DelveInsight’s ‘Surgery and Radiation Therapy in Brain Cancer–Market Insights, Competitive Landscape, and Market Forecast—2026’ report deliver an in-depth understanding of the Surgery and Radiotherapy in Brain Cancer, historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Surgery and Radiotherapy in Brain Cancer market report provides current treatment methods, emerging medical devices, market share based on treatment type, product type and end-user, current and forecasted Surgery and Radiotherapy in Brain Cancer symptoms market size from 2018 to 2026 segmented by seven major markets. The report also covers current Surgery and Radiotherapy in Brain Cancer symptoms, medical devices used in treatment, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2018–2030
Surgery and Radiotherapy in Brain Cancer Overview
A brain cancer, known as an intracranial tumor, central nervous system (CNS) tumors represent a group of diseases that have in common the abnormal development of mass lesions in the brain, spinal cord, or its coverings. A brain tumor can be classified into two main groups, i.e., primary and metastatic. A primary brain tumor is often described as “low grade” or “high grade.” A low-grade tumor generally grows slowly, but it can turn into a high-grade tumor, whereas a high-grade tumor is more likely to grow faster. Secondary brain tumors, also called brain metastases, are much more common than primary tumors in adults.
Different treatment options for treatment of brain cancers include surgery, radiation therapy, chemotherapy and targeted therapies. The treatment options and recommendations depend on several factors like the size, type, and grade of the tumor, whether the tumor is putting pressure on vital parts of the brain, if the tumor has spread to other parts of the CNS or the body, the possible side effects and finally, the treatment preferences and overall health of the patient.
Surgery might be the only treatment needed for a low-grade brain tumor, especially if all of the tumors can be removed. If there is a visible tumor remaining after surgery, radiation therapy and chemotherapy may be used. For higher-grade tumors, treatment usually begins with surgery, followed by radiation therapy and chemotherapy.
Surgery and Radiotherapy in Brain Cancer Treatment
It covers the details of conventional and current medical devices available in the Surgery and Radiotherapy in Brain Cancer market to treat brain cancer. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.
The DelveInsight Surgery and Radiotherapy in Brain Cancer market report gives a thorough understanding of Surgery and Radiotherapy in Brain Cancer symptoms by including disease diagnosis, symptoms, causes, diagnosis and treatment. It also provides Surgery and Radiotherapy in Brain Cancer treatment algorithms and treatment guidelines in the US, Europe, and Japan.
The epidemiology division’s Surgery and Radiotherapy in Brain Cancer symptoms provide insights about the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Surgery and Radiotherapy in Brain Cancer epidemiology segmented as the Incident Population of Primary Brain Tumor, Grade-Specific Patient Population of Brain Tumor, Gender-specific Patient Population of Brain Tumor, Type-specific Patient Population of Brain Tumor, Age-specific Patient Population of Brain Tumor, Treatment-specific Patient Population of Brain Tumor and Craniotomy Procedures for Primary Brain Tumor. The report includes the incident Surgery and Radiotherapy in Brain Cancer scenario in 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
The epidemiology segment also provides the Surgery and Radiotherapy in Brain Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The total 7MM prevalent cases of Surgery and Radiotherapy in Brain Cancer were 60,103 in 2020.
Products detail in the report…
Cyberknife S7: Accuray Incorporated
It is an innovative device combining speed, advanced precision, and real-time artificial intelligence-driven motion tracking and synchronization treatment delivery for all SRS and stereotactic body radiation therapy (SBRT) treatments in as little as 15 min. The CyberKnife S7 System is the next-generation CyberKnife platform, a robotic, noninvasive radiation therapy device capable of treating cancerous and benign tumors throughout the body, as well as neurologic disorders.
Products detail in the report…
The Surgery and Radiotherapy in Brain Cancer market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Surgery and Radiotherapy in Brain Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of Surgery and Radiotherapy in Brain Cancer market trend of marketed medical device by evaluating their impact based on the cost of devices, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other medical device competitors, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Surgery and Radiotherapy in Brain Cancer market in 7MM is expected to change in the study period 2018–2026.
Key Findings
This section includes a glimpse of the Surgery and Radiotherapy in Brain Cancer market in 7MM. The market size of Surgery and Radiotherapy in Brain Cancer in the seven major markets was found to be USD 79.5 million in 2020.
The United States Market Outlook
This section provides a total of Surgery and Radiotherapy in Brain Cancer market size and market size by treatment technology, by product type, by end-user and by geography in the United States.
The United States accounts for the highest Surgery and Radiotherapy in Brain Cancer market size compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.
EU-5 Countries: Market Outlook
The total Surgery and Radiotherapy in Brain Cancer market size in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.
Japan Market Outlook
The total Surgery and Radiotherapy in Brain Cancer market size in Japan are also mentioned.
The report provides insights into the market driving factors and the barriers shaping the Surgery and Radiotherapy in Brain Cancer Market. The rising incidence of brain cancer, technological advancement in the field of radiation oncology, rising use of proton therapies for the purpose of cancer treatment, adoption of radiation therapy procedures and increasing awareness program.
However, non-availability of the required healthcare infrastructure, lack of skilled radiation therapy professionals and higher treatment cost can restrain the growth of this market.
There have been various developments and collaborations in the field of Surgery and Radiation Therapy in Brain Cancer. On July 22, 2021, Accuray Incorporated announced that the medical care team at Hong Kong Sanatorium & Hospital (HKSH) in Hong Kong treated the first cancer patient in Asia using the Radixact® System, the next-generation TomoTherapy® platform, with ClearRT™ helical fan-beam kVCT imaging. Also, on July 30, 2021, IBA has highlighted its commitment to shaping the future of proton therapy by initiating a global DynamicARC®* Consortium (DAC), in collaboration with leading clinical centers. The objective of the consortium is to prepare for the clinical rollout of the DynamicARC® treatment modality within the proton therapy community using the Proteus® platform.
To keep up with current market trends, we take KOLs and SME’s opinion working on Surgery and Radiotherapy in Brain Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinions help understand and validate current and emerging therapy treatment patterns or Surgery and Radiotherapy in Brain Cancer market trends. This will support the clients in potential upcoming novel treatment by identifying the market’s overall scenario and the unmet needs.
We perform a Competitive and Market Intelligence analysis of the Surgery and Radiotherapy in Brain Cancer Market by using various Competitive Intelligence tools. The inclusion of the analysis entirely depends upon the data availability.
Market Insights:
Epidemiology Insights:
Competitive Landscape
1. Key Insights
2. Report Introduction
3. Executive Summary of Surgery and Radiation Therapy in Brain Cancer
4. Disease Background and Overview
4.1. Introduction to Brain Cancer
4.2. Types of Brain Tumor
4.2.1. Primary Brain Tumors
4.2.2. Secondary Brain Tumors
4.3. Symptoms
4.4. Risk Factors
4.5. Prevention
4.6. Brain Tumor Grading
4.7. Clinical Presentation
4.8. Diagnosis
4.8.1. Neurological Examination
4.8.2. Imaging Tests
4.8.3. Lumbar Puncture or Spinal Tap
4.8.4. Advanced Genomic Testing
4.8.5. Nuclear Medicine Bone Scan
4.8.6. Angiography
4.8.7. Electroencephalography (EEG)
4.8.8. Evoked Potentials
4.8.9. Brain Biopsy
4.9. Diagnostic Algorithm for Gliomas
4.9.1. Diagnostic guidelines for adult astrocytic and oligodendroglial gliomas by the European Association for Neurooncology (EANO)
4.10. Treatment
4.10.1. Conventional Surgery
4.10.2. Conventional Radiation Therapy
4.10.3. Radiation Surgery
4.10.4. Chemoradiation
4.10.5. Targeted Therapy
4.10.6. Laser Thermal Ablation
4.10.7. Alternating Electric Field Therapy
4.10.8. Other Drug Treatments
4.11. Treatment Algorithm
4.12. Medical Devices Used in the Treatment of Brain Cancer
4.12.1. Radiation Products
4.12.2. Surgery Products
4.13. Therapeutics used in the Treatment of Brain Cancer
5. Regulatory Scenario
5.1. United States
5.2. Europe
5.3. Japan
6. Reimbursement Scenario
6.1. United States
6.2. Europe
6.3. Japan
7. Radiation Therapy Devices: Competitive Assessment
7.1. Key Cross Competition of Marketed Radiotherapy Devices based on Approval
7.2. Key Cross Competition of Marketed Radiotherapy Devices based on Type of Therapy
7.3. Key Cross Competition of Marketed Radiotherapy Devices based on Product Type
8. Surgical Devices: Competitive Assessment
8.1. Key Cross Competition of Marketed Surgical Devices based on Approval
8.2. Key Cross Competition of Marketed Surgical Devices based on Product Type
9. Company and Product Profiles
9.1. Company and Product Profiles of Key Radiation Therapy Companies
9.1.1. Accuray
9.1.2. IBA
9.1.3. Eckert & Ziegler AG
9.1.4. Hitachi
9.1.5. Varian Medical Systems
9.1.6. GT Medical Technologies
9.1.7. Elekta AB
9.1.8. Xoft
9.1.9. IntraOp
9.1.10. Isoray
9.1.11. Mevion
9.1.12. ViewRay
9.1.13. ZEISS
9.1.14. Sensus Healthcare
9.1.15. Theragenics
9.1.16. Optivus Proton Therapy
9.1.17. S.I.T. Sordina IORT Technologies S.p.A.
9.2. Company and Product Profiles of Key Surgery Products Companies
9.2.1. Integra LifeSciences Corporation
9.2.2. Misonix Inc
9.2.3. Söring GmbH
9.2.4. Stryker Corporation
9.2.5. Olympus Corporation
9.2.6. KARL STORZ SE & Co. KG
9.2.7. B. Braun Melsungen AG
9.2.8. adeor medical AG
9.2.9. Machida Endoscopes
9.2.10. Clarus Medical
9.2.11. Medtronic plc
9.2.12. Penumbra Inc.
10. Assumptions and Rationale: Epidemiology
10.1. United States
10.2. EU5 Countries
10.3. Japan
11. 7MM: Epidemiology
11.1.1. Incident Population of Primary Brain Tumor
11.1.2. Grade-Specific Patient Population of Brain Tumor
11.1.3. Type-specific Patient Population of Brain Tumor
11.1.4. Gender-specific Patient Population of Brain Tumor
11.1.5. Age-specific Patient Population of Brain Tumor
11.1.6. Treatment-specific Patient Population of Brain Tumor
11.1.7. Craniotomy Procedures for Primary Brain Tumor
12. Country-wise Epidemiology of Brain Tumor
12.1. The United States
12.1.1 Incident Population of Primary Brain Tumor
12.1.2. Grade-Specific Patient Population of Brain Tumor
12.1.3. Type-specific Patient Population of Brain Tumor
12.1.4. Gender-specific Patient Population of Brain Tumor
12.1.5. Age-specific Patient Population of Brain Tumor
12.1.6. Treatment-specific Patient Population of Brain Tumor
12.1.7. Craniotomy Procedures for Primary Brain Tumor
12.2. Germany
12.2.1. Incident Population of Primary Brain Tumor
12.2.2. Grade-Specific Patient Population of Brain Tumor
12.2.3. Type-specific Patient Population of Brain Tumor
12.2.4. Gender-specific Patient Population of Brain Tumor
12.2.5. Age-specific Patient Population of Brain Tumor
12.2.6. Treatment-specific Patient Population of Brain Tumor
12.2.7. Craniotomy Procedures for Primary Brain Tumor
12.3. France
12.3.1. Incident Population of Primary Brain Tumor
12.3.2. Grade-Specific Patient Population of Brain Tumor
12.3.3. Type-specific Patient Population of Brain Tumor
12.3.4. Gender-specific Patient Population of Brain Tumor
12.3.5. Age-specific Patient Population of Brain Tumor
12.3.6. Treatment-specific Patient Population of Brain Tumor
12.3.7. Craniotomy Procedures for Primary Brain Tumor
12.4. Spain
12.4.1. Incident Population of Primary Brain Tumor
12.4.2. Grade-Specific Patient Population of Brain Tumor
12.4.3. Type-specific Patient Population of Brain Tumor
12.4.4. Gender-specific Patient Population of Brain Tumor
12.4.5. Age-specific Patient Population of Brain Tumor
12.4.6. Treatment-specific Patient Population of Brain Tumor
12.4.7. Craniotomy Procedures for Primary Brain Tumor
12.5. Italy
12.5.1. Incident Population of Primary Brain Tumor
12.5.2. Grade-Specific Patient Population of Brain Tumor
12.5.3. Type-specific Patient Population of Brain Tumor
12.5.4. Gender-specific Patient Population of Brain Tumor
12.5.5. Age-specific Patient Population of Brain Tumor
12.5.6. Treatment-specific Patient Population of Brain Tumor
12.5.7. Craniotomy Procedures for Primary Brain Tumor
12.6. The United Kingdom
12.6.1. Incident Population of Primary Brain Tumor
12.6.2. Grade-Specific Patient Population of Brain Tumor
12.6.3. Type-specific Patient Population of Brain Tumor
12.6.4. Gender-specific Patient Population of Brain Tumor
12.6.5. Age-specific Patient Population of Brain Tumor
12.6.6. Treatment-specific Patient Population of Brain Tumor
12.6.7. Craniotomy Procedures for Primary Brain Tumor
12.7. Japan
12.7.1. Incident Population of Primary Brain Tumor
12.7.2. Grade-Specific Patient Population of Brain Tumor
12.7.3. Type-specific Patient Population of Brain Tumor
12.7.4. Gender-specific Patient Population of Brain Tumor
12.7.5. Age-specific Patient Population of Brain Tumor
12.7.6. Treatment-specific Patient Population of Brain Tumor
12.7.7. Craniotomy Procedures for Primary Brain Tumor
13. Craniotomy Procedure Numbers
13.1. Craniotomy Procedures for Primary Brain Tumor in United States
13.2. Craniotomy Procedures for Primary Brain Tumor outside the United States
14. COVID-19 Impact Analysis on the Market
15. Assumptions and Rationale: Market Analysis
16. Surgery and Radiation Therapy in Brain Cancer: Market Analysis
16.1. Total Market Size of Surgery and Radiation Therapy in Brain Cancer in the 7MM
16.2. Market Share by Treatment Technology in 7MM
16.2.1. Conventional Surgery Market
16.2.2. Conventional Radiation Therapy Market
16.2.3. Radiation Surgery Market
16.2.4. Chemo-radiation Market
16.3 Market Share by Product Type in 7MM
16.3.1. Radiation Products Market
16.3.2. Surgery Products Market
16.4. Market Share by End-User in 7MM
16.4.1. Hospitals Market Share
16.4.2. Radiation Centers Market Share
16.5. Market Size by Geography
16.5.1. The United States Market Size
16.5.2. Germany Market Size
16.5.3. France Market Size
16.5.4. Italy Market Size
16.5.5. Spain Market Size
16.5.6. The United Kingdom Market Size
16.5.7. Japan Market Size
17. Supporting Associations
18. KOL views
19. Unmet Needs
20. Market Drivers
21. Market Barriers
22. Porter’s Five Forces Analysis
23. Appendix
23.1. Bibliography
23.2. Report Methodology
24. DelveInsight Capabilities
25. Disclaimer
26. About DelveInsight
List of Table
Table 1: Summary of Surgery and Radiation Therapy in Brain Cancer Market, Eligible Patient Pool, and Key Events (2018–2026)
Table 2: World Health Organization (WHO) Brain Tumor Grades
Table 3: World Health Organization (WHO) Brain Tumor Grades
Table 4: Clinical presentation of primary brain tumor by location
Table 5: Applicable CPT codes of IMRT/SRS/SBRT
Table 6: CPT codes for IGRT
Table 7: SRT CPT Codes if performed & documented
Table 8: Assessment based on stage
Table 9: Competitive Analysis for Radiotherapy Products used in Treatment of Brain Cancer
Table 10: Competitive Analysis for Surgical Products used in Treatment of Brain Cancer
Table 11: Company Profile: Accuray
Table 12: Company Profile: IBA
Table 13: Company Profile: Eckert & Ziegler AG
Table 14: Company Profile: Hitachi
Table 15: Company Profile: Varian Medical Systems
Table 16: Company Profile: GT Medical Technologies
Table 17: Company Profile: Elekta AB
Table 18: Company Profile: Xoft
Table 19: Company Profile: IntraOp
Table 20: Company Profile: Isoray
Table 21: Company Profile: Mevion
Table 22: Company Profile: ViewRay
Table 23: Company Profile: ZEISS
Table 24: Company Profile: Sensus Healthcare
Table 25: Company Profile: Theragenics
Table 26: Company Profile: Optivus Proton Therapy
Table 27: Company Profile: S.I.T. Sordina IORT Technologies S.p. A.
Table 28: Company Profile: Integra LifeSciences Corporation
Table 29: Company Profile: Misonix Inc
Table 30: Company Profile: Söring GmbH
Table 31: Company Profile: Stryker Corporation
Table 32: Company Profile: Olympus
Table 33: Company Profile: KARL STORZ SE & Co. KG
Table 34: Company Profile: B. Braun Group
Table 35: Company Profile: adeor medical AG
Table 36: Company Profile: Machida Endoscope
Table 37: Company Profile: Clarus Medical
Table 38: Company Profile: Medtronic plc
Table 39: Company Profile: Penumbra, Inc.
Table 40: Incident Patient Population of Primary Brain Tumor in 7MM (2018–2026)
Table 41: Grade-Specific Incident Cases in the 7MM (2018–2026)
Table 42: Type-specific Patient Population of Brain Tumor in the 7MM (2018–2026)
Table 43: Gender-Specific Incident Population of Brain Tumor in the 7MM (2018–2026)
Table 44: Age-specific Patient Population of Brain Tumor in the 7MM (2018–2026)
Table 45: Treatment-specific Patient Population of Brain Tumor in the 7MM (2018–2026)
Table 46: Craniotomy Procedures for Primary Brain Tumor in the 7MM (2018–2026)
Table 47: Incident Patient Population of Brain Tumor in the United States (2018–2026)
Table 48: Grade-Specific Incident Cases in the United States (2018–2026)
Table 49: Type-specific Patient Population of Brain Tumor in the United States (2018–2026)
Table 50: Gender-Specific Incident Population of Brain Tumor in the United States (2018–2026)
Table 51: Age-specific Patient Population of Brain Tumor in the United States (2018–2026)
Table 52: Treatment-specific Patient Population of Brain Tumor in the United States (2018–2026)
Table 53: Craniotomy Procedures for Primary Brain Tumor in the United States (2018–2026) (2018–2026)
Table 54: Incident Patient Population of Brain Tumor in Germany (2018–2026)
Table 55: Grade-Specific Incident Cases in Germany (2018–2026)
Table 56: Type-specific Patient Population of Brain Tumor in Germany (2018–2026)
Table 57: Gender-Specific Incident Population of Brain Tumor in Germany (2018–2026)
Table 58: Age-specific Patient Population of Brain Tumor in Germany (2018–2026)
Table 59: Treatment-specific Patient Population of Brain Tumor in the Germany (2018–2026)
Table 60: Craniotomy Procedures for Primary Brain Tumor in Germany (2018–2026)
Table 61: Incident Patient Population of Brain Tumor in France (2018–2026)
Table 62: Grade-Specific Incident Cases in France (2018–2026)
Table 63: Type-specific Patient Population of Brain Tumor in France (2018–2026)
Table 64: Gender-Specific Incident Population of Brain Tumor in France (2018–2026)
Table 65: Age-specific Patient Population of Brain Tumor in France (2018–2026)
Table 66: Treatment-specific Patient Population of Brain Tumor in the France (2018–2026)
Table 67: Craniotomy Procedures for Primary Brain Tumor in France (2018–2026)
Table 68: Incident Patient Population of Brain Tumor in Spain (2018–2026)
Table 69: Grade-Specific Incident Cases in Spain (2018–2026)
Table 70: Type-specific Patient Population of Brain Tumor in Spain (2018–2026)
Table 71: Gender-Specific Incident Population of Brain Tumor in Spain (2018–2026)
Table 72: Age-specific Patient Population of Brain Tumor in Spain (2018–2026)
Table 73: Treatment-specific Patient Population of Brain Tumor in Spain (2018–2026)
Table 74: Craniotomy Procedures for Primary Brain Tumor in Spain (2018–2026)
Table 75: Incident Patient Population of Brain Tumor in Italy (2018–2026)
Table 76: Grade-Specific Incident Cases in Italy (2018–2026)
Table 77: Type-specific Patient Population of Brain Tumor in Italy (2018–2026)
Table 78: Gender-Specific Incident Population of Brain Tumor in Italy (2018–2026)
Table 79: Age-specific Patient Population of Brain Tumor in Italy (2018–2026)
Table 80: Treatment-specific Patient Population of Brain Tumor in Italy (2018–2026)
Table 81: Craniotomy Procedures for Primary Brain Tumor in Italy (2018–2026)
Table 82: Incident Patient Population of Brain Tumor in United Kingdom (2018–2026)
Table 83: Grade-Specific Incident Cases in United Kingdom (2018–2026)
Table 84: Type-specific Patient Population of Brain Tumor in United Kingdom (2018–2026)
Table 85: Gender-Specific Incident Population of Brain Tumor in the United Kingdom (2018–2026)
Table 86: Age-specific Patient Population of Brain Tumor in the United Kingdom (2018–2026)
Table 87: Treatment-specific Patient Population of Brain Tumor in the United Kingdom (2018–2026)
Table 88: Craniotomy Procedures for Primary Brain Tumor in the United Kingdom (2018–2026)
Table 89: Incident Patient Population of Brain Tumor in Japan (2018–2026)
Table 90: Grade-Specific Incident Cases in Japan (2018–2026)
Table 91: Type-specific Patient Population of Brain Tumor in Japan (2018–2026)
Table 92: Gender-Specific Incident Population of Brain Tumor in Japan (2018–2026)
Table 93: Age-specific Patient Population of Brain Tumor in Japan (2018–2026)
Table 94: Treatment-specific Patient Population of Brain Tumor in Japan (2018–2026)
Table 95: Craniotomy Procedures for Primary Brain Tumor in Japan (2018–2026)
Table 96: Craniotomy Procedures for Primary Brain Tumor in the United States (2018–2026)
Table 97: Craniotomy Procedures for Primary Brain Tumor outside the United States (2018–2026)
Table 98: Total Market Size of Surgery and Radiation Therapy in Brain Cancer, in USD Million (2018–2026)
Table 99: Market Share of Conventional Surgery by Treatment Technology in USD Million (2018–2026)
Table 100: Market Share of Conventional Radiation Therapy by Treatment Technology in USD Million (2018–2026)
Table 101: Market Share of Radiation Surgery by Treatment Technology in USD Million (2018–2026)
Table 102: Market Share of Chemo-radiation by Treatment Technology in USD Million (2018–2026)
Table 103: Market Share of Radiation Product by Product Type in USD Million (2018–2026)
Table 104: Market Share of Surgery Products by Product type in USD Million (2018–2026)
Table 105: Market Share of Hospitals by End User in USD Million (2018–2026)
Table 106: Market Share of Radiation centers by End User in USD Million (2018–2026)
Table 107: Market Size of the United States for Surgery and Radiation Products in Brain Tumor by Geography in the 7MM in USD Million (2018–2026)
Table 108: Market Size of Germany for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Table 109: Market Size of France for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Table 110: Market Size of Italy for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Table 111: Market Size of Spain for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Table 112: Market Size of the United Kingdom for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Table 113: Market Size of Japan for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Table 114: Supporting Associations"
List of Figures
Figure 1: Brain Biopsy
Figure 2: Brain Biopsy
Figure 3: Endoscopic Endonasal Surgery
Figure 4: National Comprehensive Cancer Network (NCCN) Treatment Guidelines for Adult Low-grade (WHO I or II) Glioma/Pilocytic and Inflitrative Supratentorial Astrocytoma/Oligodendroglioma
Figure 5: NCCN Treatment Guidelines for Anaplastic Gliomas
Figure 6: NCCN Treatment Guidelines for Limited Brain Metastases
Figure 7: NCCN Treatment Guidelines for Extensive Brain Metastases.
Figure 8: Medical Linear Accelerator
Figure 9: Cyclotron
Figure 10: Seeds
Figure 11: Applicators
Figure 12: CyberKnife
Figure 13: GammaKnife
Figure 14: Gammatile
Figure 15: Gammatile
Figure 16: Ultrasonic system with aspirators
Figure 17: Class II Device Approval Processes in the United States
Figure 18: Approval Processes in European Countries
Figure 19: Class II Device Approval Processes in Japan
Figure 20: Healthcare Reimbursement System in the US
Figure 21: Key Cross Competition of the Marketed Radiotherapy Devices based on Approval
Figure 22: Key Cross Competition of the Marketed Radiotherapy Devices based on Type of Therapy
Figure 23: Key Cross Competition of the Marketed Radiotherapy Devices based on Product Type
Figure 24: Key Cross Competition of the Marketed Surgical Devices based on Type
Figure 25: Key Cross Competition of the Marketed Surgical Devices based on Product Type
Figure 26: Revenue (as of June 30, 2020)
Figure 27: R&D Expenses (as of June 30, 2020)
Figure 28: Revenue: IBA
Figure 29: R&D Expenses: IBA
Figure 30: Revenue: Eckert & Ziegler AG
Figure 31: R&D Expenses: Eckert & Ziegler AG
Figure 32: Revenue: Hitachi
Figure 33: Revenue: Varian Medical Systems
Figure 34: R&D Expenses: Varian Medical Systems
Figure 35: Revenue: Elekta AB
Figure 36: R&D Expenses: Elekta AB
Figure 37: Revenue: Xoft
Figure 38: Revenue: Isoray
Figure 39: R&D Expenses (as of June 30): Isoray
Figure 40: Revenue: ViewRay
Figure 41: R&D Expenses: ViewRay
Figure 42: Revenue: ZEISS
Figure 43: R&D Expenses: ZEISS
Figure 44: Revenue: Sensus Healthcare
Figure 45: R&D Expenses: Sensus Healthcare
Figure 46: Revenue: Integra LifeSciences Holdings Corporation
Figure 47: R&D Expenses: Integra LifeSciences Holdings Corporation
Figure 48: Revenue: Misonix Inc
Figure 49: R&D Expenses: Misonix Inc
Figure 50: Company Revenue: Stryker (as of December 31, of each year)
Figure 51: R&D Expenditure
Figure 52: Revenue: Olympus (as of March 31, of each year)
Figure 53: R&D Expenses: Olympus
Figure 54: Company Revenue: B. Braun Group
Figure 55: R&D Expenditure: B. Braun Group
Figure 56: Company Revenue: Medtronic (as of April 30, of each year)
Figure 57: R&D Expenses: Medtronic (as of April 30, of each year)
Figure 58: Incident Patient Population for Primary Brain Tumor in 7MM (2018–2026)
Figure 59: Grade-Specific Incident Cases in the 7MM (2018–2026)
Figure 60: Type-specific Patient Population of Brain Tumor in the 7MM (2018–2026)
Figure 61: Gender-Specific Incident Population of Brain Tumor in the 7MM (2018–2026)
Figure 62: Age-specific Patient Population of Brain Tumor in the 7MM (2018–2026)
Figure 63: Treatment-specific Patient Population of Brain Tumor in the 7MM (2018–2026)
Figure 64: Craniotomy Procedures for Primary Brain Tumor in the 7MM (2018–2026)
Figure 65: Incident Patient Population of Brain Tumor in the United States (2018–2026)
Figure 66: Grade-Specific Incident Cases in the United States (2018–2026)
Figure 67: Type-specific Patient Population of Brain Tumor in the United States (2018–2026)
Figure 68: Gender-Specific Incident Population of Brain Tumor in the United States (2018–2026)
Figure 69: Age-specific Patient Population of Brain Tumor in the United States (2018–2026)
Figure 70: Treatment-specific Patient Population of Brain Tumor in the United States (2018–2026)
Figure 71: Craniotomy Procedures for Primary Brain Tumor in the United States (2018–2026)
Figure 72: Incident Patient Population of Brain Tumor in Germany (2018–2026)
Figure 73: Grade-Specific Incident Cases in Germany (2018–2026)
Figure 74: Type-specific Patient Population of Brain Tumor in Germany (2018–2026)
Figure 75: Gender-Specific Incident Population of Brain Tumor in Germany (2018–2026)
Figure 76: Age-specific Patient Population of Brain Tumor in Germany (2018–2026)
Figure 77: Treatment-specific Patient Population of Brain Tumor in Germany (2018–2026)
Figure 78: Craniotomy Procedures for Primary Brain Tumor in Germany (2018–2026)
Figure 79: Incident Patient Population of Brain Tumor in France (2018–2026)
Figure 80: Grade-Specific Incident Cases in France (2018–2026)
Figure 81: Type-specific Patient Population of Brain Tumor in France (2018–2026)
Figure 82: Gender-Specific Incident Population of Brain Tumor in France (2018–2026)
Figure 83: Age-specific Patient Population of Brain Tumor in France (2018–2026)
Figure 84: Treatment-specific Patient Population of Brain Tumor in France (2018–2026)
Figure 85: Craniotomy Procedures for Primary Brain Tumor in France (2018–2026)
Figure 86: Incident Patient Population of Brain Tumor in Spain (2018–2026)
Figure 87: Grade-Specific Incident Cases in Spain (2018–2026)
Figure 88: Type-specific Patient Population of Brain Tumor in Spain (2018–2026)
Figure 89: Gender-Specific Incident Population of Brain Tumor in Spain (2018–2026)
Figure 90: Age-specific Patient Population of Brain Tumor in Spain (2018–2026)
Figure 91: Treatment-specific Patient Population of Brain Tumor in Spain (2018–2026)
Figure 92: Craniotomy Procedures for Primary Brain Tumor in Spain (2018–2026)
Figure 93: Incident Patient Population of Brain Tumor in Italy (2018–2026)
Figure 94: Grade-Specific Incident Cases in Italy (2018–2026)
Figure 95: Type-specific Patient Population of Brain Tumor in Italy (2018–2026)
Figure 96: Gender-Specific Incident Population of Brain Tumor in Italy (2018–2026)
Figure 97: Age-specific Patient Population of Brain Tumor in Italy (2018–2026)
Figure 98: Treatment-specific Patient Population of Brain Tumor in Italy (2018–2026)
Figure 99: Craniotomy Procedures for Primary Brain Tumor in Italy (2018–2026)
Figure 100: Incident Patient Population of Brain Tumor in United Kingdom (2018–2026)
Figure 101: Grade-Specific Incident Cases in United Kingdom (2018–2026)
Figure 102: Type-specific Patient Population of Brain Tumor in United Kingdom (2018–2026)
Figure 103: Gender-Specific Incident Population of Brain Tumor in United Kingdom (2018–2026)
Figure 104: Age-specific Patient Population of Brain Tumor in United Kingdom (2018–2026)
Figure 105: Treatment-specific Patient Population of Brain Tumor in the United Kingdom (2018–2026)
Figure 106: Craniotomy Procedures for Primary Brain Tumor in the United Kingdom (2018–2026)
Figure 107: Incident Patient Population of Brain Tumor in Japan (2018–2026)
Figure 108: Grade-Specific Incident Cases in Japan (2018–2026)
Figure 109: Type-specific Patient Population of Brain Tumor in Japan (2018–2026)
Figure 110: Gender-Specific Incident Population of Brain Tumor in Japan (2018–2026)
Figure 111: Age-specific Patient Population of Brain Tumor in Japan (2018–2026)
Figure 112: Treatment-specific Patient Population of Brain Tumor in Japan (2018–2026)
Figure 113: Craniotomy Procedures for Primary Brain Tumor in Japan (2018–2026)
Figure 114: Craniotomy Procedures for Primary Brain Tumor in the United States (2018–2026)
Figure 115: Craniotomy Procedures for Primary Brain Tumor outside the United States (2018–2026)
Figure 116: COVID-19 Impact Analysis on the Market Size in USD Million (2018–2026)
Figure 117: Total Market Size of Surgery and Radiation Therapy in Brain Cancer, in USD Million (2018–2026)
Figure 118: Market Share of Conventional Surgery by Treatment Technology in USD Million (2018–2026)
Figure 119: Market Share of Conventional Radiation Therapy by Treatment Technology in USD Million (2018–2026)
Figure 120: Market Share of Radiation Surgery by Treatment Technology in USD Million (2018–2026)
Figure 121: Market Share of Chemo-radiation by Treatment Technology in USD Million (2018–2026)
Figure 122: Market Share of Radiation Products by Product type in USD Million (2018–2026)
Figure 123: Market Share of Surgery Products by Product type in USD Million (2018–2026)
Figure 124: Market Share of Hospitals by End User in USD Million (2018–2026)
Figure 125: Market Share of Radiation centers by End User in USD Million (2018–2026)
Figure 126: Market Size of the United States for Surgery and Radiation Products in Brain Tumor by Geography in the 7MM in USD Million (2018–2026)
Figure 127: Market Size of Germany for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Figure 128: Market Size of France for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Figure 129: Market Size of Italy for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Figure 130: Market Size of Spain for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Figure 131: Market Size of the United Kingdom for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Figure 132: Market Size of Japan for Surgery and Radiation Products in Brain Tumor by Geography in USD Million (2018–2026)
Accuray Incorporated
Ion Beam Applications SA
Eckert & Ziegler
Hitachi, Ltd.
Varian Medical Systems Inc.
GT Medical Technologies Inc.
Elekta AB (publ)
Xoft, Inc.
IntraOp Medical, Inc
Isoray Inc.
Mevion
ViewRay
ZEISS
Sensus Healthcare
Theragenics
Optivus Proton Therapy
S.I.T. Sordina IORT Technologies S.p.A.
Integra LifeSciences Corporation
Misonix Inc
Söring GmbH
Stryker Corporation
Olympus Corporation
KARL STORZ SE & Co. KG
B. Braun Melsungen AG
adeor medical AG
Machida Endoscopes
Clarus Medical
Medtronic plc
Penumbra Inc.
